336 related articles for article (PubMed ID: 25164760)
1. Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents.
Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
Eur J Med Chem; 2014 Oct; 86():211-8. PubMed ID: 25164760
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and anti-breast cancer evaluation of new triarylethylene analogs bearing short alkyl- and polar amino-/amido-ethyl chains.
Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
Bioorg Med Chem Lett; 2016 Apr; 26(8):1963-9. PubMed ID: 26972118
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
[TBL] [Abstract][Full Text] [Related]
4. Anticancer phytochemical analogs 37: synthesis, characterization, molecular docking and cytotoxicity of novel plumbagin hydrazones against breast cancer cells.
Dandawate P; Ahmad A; Deshpande J; Swamy KV; Khan EM; Khetmalas M; Padhye S; Sarkar F
Bioorg Med Chem Lett; 2014 Jul; 24(13):2900-4. PubMed ID: 24835626
[TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents.
Elghazawy NH; Engel M; Hartmann RW; Hamed MM; Ahmed NS; Abadi AH
Future Med Chem; 2016; 8(3):249-56. PubMed ID: 26898104
[TBL] [Abstract][Full Text] [Related]
7. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
ter Haar E; Day BW
Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and bioevaluation of novel 6-(4-Hydroxypiperidino)naphthalen-2-ol-based potential Selective Estrogen Receptor Modulators for breast cancer.
Jha A; Yadav Y; Naidu AB; Rao VK; Kumar A; Parmar VS; MacDonald WJ; Too CK; Balzarini J; Barden CJ; Cameron TS
Eur J Med Chem; 2015 Mar; 92():103-14. PubMed ID: 25544690
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
10. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
Power KA; Thompson LU
Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
[TBL] [Abstract][Full Text] [Related]
11. Development of constrained tamoxifen mimics and their antiproliferative properties against breast cancer cells.
Archana S; Geesala R; Rao NB; Satpati S; Puroshottam G; Panasa A; Dixit A; Das A; Srivastava AK
Bioorg Med Chem Lett; 2015 Feb; 25(3):680-4. PubMed ID: 25529734
[TBL] [Abstract][Full Text] [Related]
12. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
13. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.
Kelly PM; Keely NO; Bright SA; Yassin B; Ana G; Fayne D; Zisterer DM; Meegan MJ
Molecules; 2017 Aug; 22(9):. PubMed ID: 28858267
[TBL] [Abstract][Full Text] [Related]
14. An estrogen receptor targeted ruthenium complex as a two-photon photodynamic therapy agent for breast cancer cells.
Zhao X; Li M; Sun W; Fan J; Du J; Peng X
Chem Commun (Camb); 2018 Jun; 54(51):7038-7041. PubMed ID: 29873358
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of 2,2-dimethyl-chroman-based stereochemically flexible and constrained anti-breast cancer agents.
Nainawat KS; Gupta K; Gupta N; Singh R; Mishra D; Nirwan A; Verma M; Singh A; Vasudev PG; Khan F; Mishra DP; Gupta A
Bioorg Med Chem Lett; 2024 Aug; 108():129789. PubMed ID: 38729318
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of novel biisoquinoline derivatives against breast cancers.
Jaiswal AS; Hirsch-Weil D; Proulx ER; Hong S; Narayan S
Bioorg Med Chem Lett; 2014 Oct; 24(20):4850-3. PubMed ID: 25240616
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of targeted dibenzo[b,f]thiepines and dibenzo[b,f]oxepines as potential lead molecules with promising anti-breast cancer activity.
Ansari MI; Hussain MK; Arun A; Chakravarti B; Konwar R; Hajela K
Eur J Med Chem; 2015 Jun; 99():113-24. PubMed ID: 26067208
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and cancer cell growth inhibitory activity of icaritin derivatives.
Wang C; Wu P; Shi JF; Jiang ZH; Wei XY
Eur J Med Chem; 2015 Jul; 100():139-50. PubMed ID: 26079090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
